IART
Integra LifeSciences Holdings Corporation NASDAQ$10.65
Mkt Cap $830.0M
52w Low $8.70
25.0% of range
52w High $16.49
50d MA $10.12
200d MA $12.42
P/E (TTM)
-1.6x
EV/EBITDA
-8.4x
P/B
0.8x
Debt/Equity
1.9x
ROE
-49.5%
P/FCF
-30.7x
RSI (14)
—
ATR (14)
—
Beta
1.06
50d MA
$10.12
200d MA
$12.42
Avg Volume
807.7K
About
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, ce…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | BMO | 0.79 | 0.83 | +5.1% | 11.33 | -1.9% | +0.4% | -7.9% | -6.8% | -8.3% | -12.7% | -19.5% | — |
| Oct 30, 2025 | BMO | 0.43 | 0.54 | +25.6% | 11.81 | +0.8% | +1.7% | -2.7% | -4.3% | -3.5% | -5.0% | +10.6% | — |
| Jul 31, 2025 | BMO | 0.43 | 0.45 | +4.7% | 13.14 | -3.2% | -6.3% | -4.4% | -3.1% | -5.9% | -3.9% | +15.4% | — |
| May 5, 2025 | BMO | 0.43 | 0.41 | -4.7% | 13.28 | +0.5% | -4.0% | -4.1% | -2.9% | -7.8% | +2.9% | -1.4% | — |
| Feb 25, 2025 | BMO | 0.86 | 0.97 | +12.8% | 24.72 | -0.9% | -4.5% | -6.7% | -6.1% | -9.1% | -11.4% | -11.0% | — |
| Nov 4, 2024 | BMO | 0.39 | 0.41 | +5.1% | 24.12 | +0.2% | +3.3% | +10.7% | +5.8% | +2.7% | +5.5% | -0.0% | — |
| Jul 29, 2024 | BMO | 0.62 | 0.63 | +1.6% | 25.42 | -2.8% | -1.5% | -2.4% | -3.2% | -5.4% | -12.1% | -19.9% | — |
| May 6, 2024 | BMO | 0.55 | 0.55 | +0.0% | 23.14 | -2.2% | +8.4% | +7.6% | +9.3% | +12.3% | +13.3% | +37.3% | — |
| Feb 28, 2024 | BMO | 0.90 | 0.89 | -1.1% | 38.67 | +0.9% | -4.6% | -6.9% | -7.1% | -5.5% | -6.6% | -10.2% | — |
| Oct 25, 2023 | BMO | 0.78 | 0.76 | -2.6% | 35.34 | -0.8% | +0.5% | -3.2% | -0.8% | +1.7% | +4.3% | +11.9% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15 | Truist | Maintains | Hold → Hold | — | $11.06 | $10.60 | -4.2% | -0.3% | -2.0% | +0.7% | +0.9% | -4.9% |
| Apr 15 | Argus | Downgrade | Buy → Hold | — | $11.06 | $10.60 | -4.2% | -0.3% | -2.0% | +0.7% | +0.9% | -4.9% |
| Mar 11 | Citigroup | Maintains | Sell → Sell | — | $9.55 | $9.45 | -1.0% | +0.6% | -4.0% | -3.2% | -5.7% | -4.7% |
| Feb 27 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $11.33 | $11.12 | -1.9% | +0.4% | -7.9% | -6.8% | -8.3% | -12.7% |
| Nov 3 | Truist | Maintains | Hold → Hold | — | $12.01 | $11.77 | -2.0% | -4.3% | -5.9% | -5.1% | -6.6% | +0.2% |
| Oct 31 | JP Morgan | Maintains | Underweight → Underweight | — | $11.81 | $11.90 | +0.8% | +1.7% | -2.7% | -4.3% | -3.5% | -5.0% |
| Oct 31 | Citigroup | Maintains | Sell → Sell | — | $11.81 | $11.90 | +0.8% | +1.7% | -2.7% | -4.3% | -3.5% | -5.0% |
| Oct 15 | Truist | Maintains | Hold → Hold | — | $14.40 | $14.48 | +0.6% | -1.2% | +1.5% | +4.7% | +9.0% | +10.3% |
| Oct 7 | Citigroup | Maintains | Sell → Sell | — | $14.50 | $14.65 | +1.0% | -0.5% | +2.1% | -2.3% | -8.0% | -6.1% |
| May 9 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $12.89 | $12.89 | +0.0% | -5.0% | +6.1% | +4.8% | +0.2% | +0.9% |
Recent Filings
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
The extension of the asset-backed lending facility to 2029 reduces near-term refinancing risk and provides BNS and IART with enhanced operational flexibility, supporting continued working capital financing stability.
Apr 15
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
The company disclosed investor presentation materials on March 17, 2026, suggesting upcoming investor meetings or conferences that could signal strategic updates or capital plans worth monitoring.
Mar 17
8-K
Integra LifeSciences Holdings -- 8-K Filing
Integra LifeSciences (IART) disclosed adjusted EPS guidance without GAAP reconciliation due to unpredictability of certain expense items, limiting investor transparency on earnings quality.
Feb 26
8-K · 5.02
!!! Very High
Kyverna Therapeutics, Inc. -- 8-K 5.02: Executive Change
Kyverna Therapeutics appointed Andrew Miller as a Class III director, expanding its board composition to strengthen governance and potentially bringing new strategic expertise to the company.
Feb 24
8-K · 5.02
!!! Very High
Piper Sandler Companies -- 8-K 5.02: Executive Change
Piper Sandler Companies appointed Stuart M. Essig as a director, expanding its board leadership potentially with his industry expertise.
Feb 4
Data updated apr 25, 2026 2:40pm
· Source: massive.com